bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement to an Item 8.01 – Other Events

Item 8.01Other Events

On October 4, 2017, bluebird bio, Inc. (“bluebird”) issued a press release announcing the publication of interim data from the Starbeam Study of bluebird’s Lenti-D drug product in patients with cerebral adrenoleukodystrophy in the New England Journal of Medicine, and the presentation of additional follow-up data at the Child Neurology Society Annual Meeting. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

bluebird bio, Inc. Exhibit
EX-99.1 2 blue-ex991_6.htm EX-99.1 blue-ex991_6.htm   Exhibit 99.1   bluebird bio Announces Publication of Interim Data from Starbeam Study of  Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine     – Additional follow-up data to be included in poster presentation at Child Neurology Society (CNS) Annual Meeting –   – 15/17 (88%) of the patients infused with Lenti-D drug product remain alive and free of major functional disabilities (MFDs),…
To view the full exhibit click here

About bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.